If you are looking for information about Rudy Tanzi you should find this of interest:
The Plan to End Alzheimer's Disease by 2020 (Podcast)
Dr. Tanzi is a dynamic speaker and manages to make complex science understandable and interesting. I hope you will join and encourage others to do so as well.
The webinar is no longer available.
Note from Bob DeMarco: I recommend this webinar. I suggest you use the link and register early.
This live presentation by Dr. Rudy Tanzi will be conducted over the internet. Each guest will participate through their own computer and phone. Dr. Tanzi will talk about recent breakthrough work and progress on the path to a cure.
Dr. Rudy Tanzi is a world-renowned leader in the study of Alzheimer's disease genetics. He is the Joseph P. and Rose F. Kennedy Professor of Neurology at the Harvard Medical School, and the Director of the Genetics and Aging Research Unit at Massachusetts General Hospital.
Dr. Tanzi has identified several Alzheimer's disease genes, including the first Alzheimer's gene, the beta-amyloid protein precursor. His work in the Alzheimer's Genome Project, a Cure Alzheimer's Fund supported project, was recognized by TIME magazine as one of the top 10 medical breakthroughs of 2008.
From Tanzi's profile on Neuroscience @ Harvard
My research is primarily aimed at identifying and characterizing Alzheimer’s disease (AD)-associated gene mutations/variants with the ultimate goal of defining the molecular, cellular, and biochemical events leading to neuronal cell death in the brains of AD patients.
A significant portion of AD is caused by the inheritance of defective genes, while specific gene variants can increase lifetime risk for the disease.
To date, four different genes have been implicated to play a role in familial Alzheimer's disease (FAD). My lab has been involved with the discovery of three of these genes, including (the amyloid protein precursor [APP], presenilin 1 [PSEN1], and presenilin 2 [PSEN2]) that harbor defects causing "early-onset" forms of the disease with virtually 100% certainty usually under 60 years old.
Our studies are targeted toward determining the pathogenic mechanisms by which defects or variants carried by these genes contribute to the neurodegenerative process in the brains of patients with AD.
For this purpose, we are employing cell-based and animal models including Drosophila. An in-depth understanding of the normal function of the AD genes and how mutations and variants of these genes can lead to amyloid deposition, neuronal cell death, and dementia will be invaluable for the development of novel treatments for AD.
Along these lines, our current focus is to translate knowledge gained regarding genetic mechanisms of neuropathogenesis of AD into drug discovery. We are also searching for genes that cause autism and related disorders.
- 60 Good Reasons to Subscribe to the Alzheimer's Reading Room
- Alzheimer's CareGiving -- Insight and Advice
- Test Your Memory for Alzheimer's (5 Best Self Assessment Tests)
- Communicating in Alzheimer's World
- Worried About Alzheimer's Disease -- You Should Be
- What is Alzheimer's? What are the Eight Types of Dementia?
- Does the Combination of Aricept and Namenda Help Slow the Rate of Decline in Alzheimer's Patients
- Alzheimer's Disease Statistics
- Is it Really Alzheimer's or Something Else?
- Ten Symptoms of Early Stage Alzheimer's
- Ten Tips for Communicating with an Alzheimer’s Patient
Bob DeMarco is the Founderof the Alzheimer's Reading Room and an Alzheimer's caregiver. Bob has written more than 2,260 articles with more than 285,000 links on the Internet. Bob resides in Delray Beach, FL.
Original content Bob DeMarco, the Alzheimer's Reading Room